Radiolabeled Monoclonal Antibody Imaging of Tumors and Positron Emission Tomogra

这些研究旨在发展检测和治疗恶性肿瘤的改进方法。我们的小组在国家癌症研究所的各个实验室进行初步筛选后，对抗体进行临床前评估，并开发这些抗体用于临床应用。临床试验评价其药代动力学和剂量学是由我组完成的。与Waldmann博士（PI）合作的放射免疫治疗试验正在进行中，我们使用人源抗tac单克隆抗体。在PET和[O-15]水中使用[F-18] FDG进行肿瘤检测、随访和血流量测量的各种方案正在进行中。我们已经开始临床前研究，评估肿瘤治疗的抗体预靶向性，并已证明Y-90和Bi-213的治疗效果。

These studies are designed to develop improved methods for detecting and treating malignancies. Our group performs preclinical evaluation of antibodies that appear to be promising after initial screening by various laboratories at the National Cancer Institute and develops these antibodies for clinical application. The clinical trials evaluating their pharmacokinetics and dosimetry are performed by our group. A collaborative radioimmunotherapy trial with Dr. Waldmann (PI), in which we used humanized anti-tac monoclonal antibody, is ongoing. Various protocols using [F-18] FDG in PET and [O-15] water for tumor detection, followup, and blood flow measurements are ongoing. We have begun preclinical studies evaluating pretargeting of antibodies for tumor therapy and have demonstrated therapeutic responses with Y-90 and Bi-213.